Autologous hematopoietic stem cell transplantation with reduced-intensity conditioning in multiple sclerosis

Experimental Hematology

Volumn 40, Issue 11, 2012, Pages 892-898

  Shevchenko, Jury L ^a   Kuznetsov, Alexey N ^a   Ionova, Tatyana I ^a   Melnichenko, Vladimir Y ^a   Fedorenko, Denis A ^a   Kartashov, Andrei V ^a   Kurbatova, Kira A ^a   Gorodokin, Gary I ^b   Novik, Andrei A ^a  

^a Pirogov National Medical Surgical Center   (Russian Federation)

^b Health Outcomes Department   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; BETA INTERFERON; CARMUSTINE; CYTARABINE; ETOPOSIDE; GLATIRAMER; GRANULOCYTE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN; LOMUSTINE; MELPHALAN; MEROPENEM; MITOXANTRONE; STEROID; THYMOCYTE ANTIBODY; VANCOMYCIN;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; DISEASE COURSE; DRUG EFFICACY; DRUG SAFETY; EARLY INTERVENTION; FEMALE; FOLLOW UP; HIGH DOSE IMMUNOSUPPRESSIVE THERAPY; HUMAN; IMMUNOSUPPRESSIVE TREATMENT; MAJOR CLINICAL STUDY; MALE; MULTIPLE SCLEROSIS; NUCLEAR MAGNETIC RESONANCE IMAGING; OPEN STUDY; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; PROSPECTIVE STUDY; QUALITY OF LIFE; REDUCED INTENSITY CONDITIONING; SALVAGE THERAPY; STEM CELL MOBILIZATION; SURVIVAL RATE; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME; TREATMENT OUTCOME; TREATMENT RESPONSE;

ADULT; DISEASE-FREE SURVIVAL; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; MALE; MULTIPLE SCLEROSIS; PROSPECTIVE STUDIES; QUALITY OF LIFE; TRANSPLANTATION CONDITIONING;

EID: 84867405187     PISSN: 0301472X     EISSN: 18732399     Source Type: Journal    
DOI: 10.1016/j.exphem.2012.07.003     Document Type: Article

References (36)

1. Weinshenker B.G. The natural history of multiple sclerosis. Neurol Clin 1995, 3:119-146.
2. Weinshenker B.G., Bass B., Rice G.P., et al. The natural history of multiple sclerosis: a geographically based study. I. Clinical course and disability. Brain 1989, 112:133-146.
3. Compston A., Ebers G., Lassmann H., McDonald I., Matthews B., Wekerle H. McAlpine's Multiple Sclerosis 1998, Churchill Livingstone, Edinburgh. 3rd ed.
4. Hafler D.A. Multiple sclerosis. J. Clin Invest 2004, 113:788-794.
5. Kappos L. Therapy. Multiple Sclerosis 1997, 148-167. Cambridge University Press, Boston. J. Kesselring, W.I. McDonald (Eds.).
6. Burt R.K., Cohen B., Rose J., et al. Hematopoietic stem cell transplantation for multiple sclerosis. Arch Neurol 2005, 62:860-864.
7. Fassas A., Anagnostopoulos A., Kazis A., et al. Autologous stem cell transplantation in progressive multiple sclerosis-an interim analysis of efficacy. J Clin Immunol 2000, 20:24-30.
8. Brenner M.K. Haematopoietic stem cell transplantation for autoimmune disease: limits and future potential. Best Pract Res Clin Haematol 2004, 17:359-374.
9. Burt R.K., Cohen B.A., Russell E., et al. Hematopoietic stem cell transplantation for progressive multiple sclerosis; failure of a total body irradiation-based conditioning regimen to prevent disease progression in patients with high disability scores. Blood 2003, 102:2373-2378.
10. Burt R.K., Cohen B., Lobeck L., Traynor A.E. Autologous hematopoietic stem cell transplantation in multiple sclerosis: importance of disease stage on outcome [abstract]. Neurology 2003, 40(suppl). Abstract 150.
11. Fassas A., Nash R. Multiple sclerosis. Best Pract Res Clin Hematol 2004, 17:247-262.
12. Fassas A., Passweg J.R., Anagnostopoulos A., et al. Hematopoietic stem cell transplantation for multiple sclerosis. A retrospective multicenter study. J Neurol 2002, 249:1088-1097.
13. Kozak T., Havrdova E., Pit'ha J., et al. High-dose immunosuppressive therapy with PBPC support in the treatment of poor risk multiple sclerosis. Bone Marrow Transplant 2000, 25:525-531.
14. Nash R.A., Bowen J.D., McSweeney P.A., et al. High-dose immunosuppressive therapy and autologous peripheral blood stem cell transplantation for severe multiple sclerosis. Blood 2003, 102:2364-2372.
15. Freedman M., Atkins H., Arnold D., Bar- Or A. Immuneablation and autologous stem cell transplantation for aggressive multiple sclerosis: interim 5-year report. Mult Scler 2007, 13(suppl 2):S22. on behalf of the Canadian BMT Study Group, (abstract).
16. Saccardi R., Kozak T., Tyndall C., et al. Autologous stem cell transplantation for progressive multiple sclerosis: update of the European Group for Blood and Marrow Transplantation Autoimmune Diseases Working Party database. Mult Scler 2006, 12:814-823.
17. Ni X.S., Ouyang J., Zhu W.H., Wang C., Chen B. Autologous hematopoietic stem cell transplantation for progressive multiple sclerosis: report of efficacy and safety at three yr of follow up in 21 patients. Clin Transplant 2006, 20:485-489.
18. Krasulova E., Trneny M., Kozak T., et al. High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience. Mult Scler 2010, 16:685-693.
19. Hamerschlak N., Rodrigues M., Moraes D.A., et al. Brazilian experience with two conditioning regimens in patients with multiple sclerosis: BEAM/horse ATG and CY/rabbit ATG. Bone Marrow Transplant 2010, 45:239-248.
20. Burt R., Loh Y., Cohen B., et al. Autologous non-myeloablative haemopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: a phase I/II study. Lancet Neurol 2009, 8:244-253.
21. Comi G., Kappos L., Clanet M., et al. Guidelines for autologous blood and marrow stem cell transplantation in multiple sclerosis: a consensus report written on behalf of the European Group for Blood and Marrow Transplantation and the European Charcot Foundation. J Neurol 2000, 247:376-382.
22. Mancardi G., Saccardi R. Autologous haematopoietic stem-cell transplantation in multiple sclerosis. Lancet Neurol 2008, 7:626-636.
23. Tyndall A., Fassas A., Passweg J., et al. Autologous haematopoietic stem cell transplants for autoimmune disease-feasibility and transplant-related mortality. Autoimmune Disease and Lymphoma Working Parties of the European Group for Blood and Marrow Transplantation, the European League Against Rheumatism and the International Stem Cell Project for Autoimmune Disease. Bone Marrow Transplant 1999, 24:729-734.
24. Gratwohl A., Passweg J., Bocelli-Tyndall C., et al. Autologous hematopoietic stem cell transplantation for autoimmune diseases. Bone Marrow Transplant 2005, 35:869-879.
25. Burt R.K., Marmont A., Oyama Y., et al. Randomized controlled trials of autologous hematopoietic stem cell transplantation for autoimmune diseases: the evolution from myeloablative transplant regimens. Arthritis Rheum 2006, 54:3750-3760.
26. Reston J.T., Uhl S., Treadwell J.R., Nash R.A., Schoelles K. Autologous hematopoietic cell transplantation for multiple sclerosis: a systematic review. Mult Scler 2011, 17:204-213.
27. Saccardi R., Mancardi G.L., Solari A., et al. Autologous HSCT for severe progressive multiple sclerosis in a multicenter trial: impact on disease activity and quality of life. Blood 2005, 105:2601-2607.
28. Novik A., Ionova T., Bisaga G., et al. Clinical and quality of life responses to high-dose chemotherapy plus autologous stem cell transplantation in patients with multiple sclerosis: two case reports. Cytotherapy 2005, 7:363-367.
29. Shevchenko Y., Novik A., Kuznetsov A., et al. High-dose immunosuppressive therapy with autologous hematopoietic stem cell transplantation as a treatment option in multiple sclerosis. Exp Hematol 2008, 36:922-929.
30. Chen B., Zhou M., Ouyang J., et al. Long-term efficacy of autologous haematopoietic stem cell transplantation in multiple sclerosis at a single institution in China. Neurol Sci 2012, 33(suppl 4):881-886.
31. Snowden J.A., Saccardi R., Allez M., et al. Haematopoietic SCT in severe autoimmune disease: updated guidelines of the European Group for Blood and Marrow Transplantation. Bone Marrow Transplant 2012, 47:770-790.
32. Rogojan C., Frederiksen J.L. Hematopoietic stem cell transplantation in multiple sclerosis. Acta Neurol Scand 2009, 120:371-382.
33. Muraro P.A., McFarland H.F., Martin R. Immunological aspects of multiple sclerosis with emphasis on the potential use of autologous hemopoietic stem cell transplantation. Stem Cell Therapy for Autoimmune Disease 2004, 277-283. Landes Bioscience, Georgetown, TX. R.K. Burt, A.M. Marmont (Eds.).
34. McDonald W.I., Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001, 50(suppl 1):121-127.
35. Hays RD, Sherbourne CD, Mazel RM. User's Manual for Medical Outcomes Study (MOS) Core measures of health-related quality of life. RAND Corporation, MR-162-RC. Available at: Accessed 1995. http://www.rand.org.
36. Fassas A., Anagnostopoulos A., Kasis A., et al. Peripheral blood stem cell transplantation in the treatment of progressive multiple sclerosis: first results of a pilot study. Bone Marrow Transplant 1997, 20:631-638.